Latest News and Press Releases

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): I henhold til artikel 19 i EU-forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af ledende...

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the...

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B):  I henhold til selskabets vederlagspolitik, som er vedtaget på selskabets ordinære generalforsamling den 16. marts 2026, og i tråd med selskabets sædvanlige...

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): According to the company’s remuneration policy adopted at the company's Annual General Meeting on 16 March 2026 and in line with the company’s usual practice,...

Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European...

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B):  ALK-Abelló A/S afholdt ordinær generalforsamling den 16. marts 2026. På generalforsamlingen skete følgende: Årsrapport 2025 blev godkendt, og der blev...

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B):  ALK-Abelló A/S held its Annual General Meeting on 16 March 2026. The Annual General Meeting transacted the following business: Approval of the annual...

ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis.

Ordinær generalforsamling i ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) finder sted mandag den 16. marts 2026 kl. 16.00 hos ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm i henhold til vedhæftede...

The Annual General Meeting of ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) will take place on Monday, 16 March 2026 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The...